Skip to main content
Top
Published in: Drugs & Aging 10/2008

01-10-2008 | Original Research Article

Concurrent Use of Anticholinergic Drugs and Cholinesterase Inhibitors

Register-Based Study of Over 700 000 Elderly Patients

Authors: Dr Kristina Johnell, Johan Fastbom

Published in: Drugs & Aging | Issue 10/2008

Login to get access

Abstract

Background: Although cholinesterase inhibitors are used for the treatment of Alzheimer’s disease, the clinical benefits of these drugs are being questioned. Anticholinergic drugs have the opposite pharmacological action to cholinesterase inhibitors, and may antagonize the effects of cholinesterase inhibitors. Therefore, this drug combination should be avoided. Nevertheless, high rates of concurrent use of anticholinergic drugs and cholinesterase inhibitors have been reported in the US. To the authors’ knowledge, use of this inappropriate drug combination has not been studied outside North America.
Objective: To investigate (i) whether anticholinergic drug use is more common among users than non-users of cholinesterase inhibitors, and (ii) which factors are associated with use of anticholinergic drugs among users of cholinesterase inhibitors.
Methods: We analysed data on age, sex, type of residential area (urban/rural) and drugs dispensed for patients aged ≥75 years registered in the Swedish Prescribed Drug Register from October to December 2005 (n = 731 105). The prevalence of use of anticholinergic drugs in users of cholinesterase inhibitors was compared with that in non-users of cholinesterase inhibitors and logistic regression was used to study the association between use of cholinesterase inhibitors and anticholinergic drugs. Logistic regression was also used to analyse whether age, sex, type of residential area or number of dispensed drugs was associated with use of anticholinergic drugs among users of cholinesterase inhibitors (n = 18 326).
Results: Anticholinergic drug use was more common among cholinesterase inhibitor users than non-users, particularly in men, of whom 9% who were taking cholinesterase inhibitors were dispensed anticholinergic drugs compared with 5% who were not taking cholinesterase inhibitors. Use of cholinesterase inhibitors was associated with use of anticholinergic drugs in men (odds ratio 1.23; 95% CI 1.13, 1.35), after adjustment for age, type of residential area and number of dispensed drugs. Male sex and use of many drugs were independently associated with concurrent use of anticholinergic drugs and cholinesterase inhibitors.
Conclusion: Anticholinergic drug use is more common among cholinesterase inhibitor users than non-users, even though anticholinergic drugs may antagonize the effect of cholinesterase inhibitors. Hence, if the true clinical effects of cholinesterase inhibitors are to be accurately assessed, they need to be studied in the absence of anticholinergic drugs.
Literature
1.
go back to reference Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry 2001; 62Suppl. 21: 11–4PubMed Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry 2001; 62Suppl. 21: 11–4PubMed
2.
go back to reference Wilkinson DG, Francis FT, Schwam E, et al. Cholinesterase inhibitors used in the treatment of Alzheimer’s disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging 2004; 21(7): 453–78PubMedCrossRef Wilkinson DG, Francis FT, Schwam E, et al. Cholinesterase inhibitors used in the treatment of Alzheimer’s disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging 2004; 21(7): 453–78PubMedCrossRef
3.
go back to reference Olsen CE, Poulsen HD, Lublin HK. Drug therapy of dementia in elderly patients: a review. Nord J Psychiatry 2005; 59(2): 71–7PubMedCrossRef Olsen CE, Poulsen HD, Lublin HK. Drug therapy of dementia in elderly patients: a review. Nord J Psychiatry 2005; 59(2): 71–7PubMedCrossRef
4.
go back to reference Ringman JM, Cummings JL. Current and emerging pharmacological treatment options for dementia. Behav Neurol 2006; 17(1): 5–16PubMed Ringman JM, Cummings JL. Current and emerging pharmacological treatment options for dementia. Behav Neurol 2006; 17(1): 5–16PubMed
5.
go back to reference Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, et al. Cholinesterase inhibitors for patients with Alzheimer’s disease: systematic review of randomised clinical trials. BMJ 2005 Aug 6; 331(7512): 321–7PubMedCrossRef Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, et al. Cholinesterase inhibitors for patients with Alzheimer’s disease: systematic review of randomised clinical trials. BMJ 2005 Aug 6; 331(7512): 321–7PubMedCrossRef
6.
go back to reference Iliffe S. The National Institute for Health and Clinical Excellence (NICE) and drug treatment for Alzheimer’s disease. CNS Drugs 2007; 21(3): 177–84PubMedCrossRef Iliffe S. The National Institute for Health and Clinical Excellence (NICE) and drug treatment for Alzheimer’s disease. CNS Drugs 2007; 21(3): 177–84PubMedCrossRef
8.
go back to reference Martin RM, Rink E, Wilkinson DG, et al. Did knowledge, opinions, background, and health authority advice influence early prescribing of the novel Alzheimer’s disease drug done-pezil in general practice? National postal survey. Pharmacoepidemiol Drug Saf 1999 Oct; 8(6): 413–22PubMedCrossRef Martin RM, Rink E, Wilkinson DG, et al. Did knowledge, opinions, background, and health authority advice influence early prescribing of the novel Alzheimer’s disease drug done-pezil in general practice? National postal survey. Pharmacoepidemiol Drug Saf 1999 Oct; 8(6): 413–22PubMedCrossRef
9.
go back to reference Oude Voshaar RC, Burns A, Olde Rikkert MG. Alarming arbitrariness in EU prescription and reimbursement criteria for anti-dementia drugs. Int J Geriatr Psychiatry 2006 Jan; 21(1): 29–31PubMedCrossRef Oude Voshaar RC, Burns A, Olde Rikkert MG. Alarming arbitrariness in EU prescription and reimbursement criteria for anti-dementia drugs. Int J Geriatr Psychiatry 2006 Jan; 21(1): 29–31PubMedCrossRef
10.
go back to reference Purandare N, Swarbrick C, Fischer A, et al. Cholinesterase inhibitors for Alzheimer’s disease: variations in clinical practice in the north-west of England. Int J Geriatr Psychiatry 2006 Oct; 21(10): 961–4PubMedCrossRef Purandare N, Swarbrick C, Fischer A, et al. Cholinesterase inhibitors for Alzheimer’s disease: variations in clinical practice in the north-west of England. Int J Geriatr Psychiatry 2006 Oct; 21(10): 961–4PubMedCrossRef
11.
go back to reference Hansen RA, Gartlehner G, Lohr KN, et al. Functional outcomes of drug treatment in Alzheimer’s disease: a systematic review and meta-analysis. Drugs Aging 2007; 24(2): 155–67PubMedCrossRef Hansen RA, Gartlehner G, Lohr KN, et al. Functional outcomes of drug treatment in Alzheimer’s disease: a systematic review and meta-analysis. Drugs Aging 2007; 24(2): 155–67PubMedCrossRef
12.
go back to reference Defilippi JL, Crismon ML. Drug interactions with cholinesterase inhibitors. Drugs Aging 2003; 20(6): 437–44PubMedCrossRef Defilippi JL, Crismon ML. Drug interactions with cholinesterase inhibitors. Drugs Aging 2003; 20(6): 437–44PubMedCrossRef
13.
go back to reference Edwards KR, O’Connor JT. Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors. J Am Geriatr Soc 2002 Jun; 50(6): 1165–6PubMedCrossRef Edwards KR, O’Connor JT. Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors. J Am Geriatr Soc 2002 Jun; 50(6): 1165–6PubMedCrossRef
14.
go back to reference Ancelin ML, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006 Feb 25; 332(7539): 455–9PubMedCrossRef Ancelin ML, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006 Feb 25; 332(7539): 455–9PubMedCrossRef
15.
go back to reference Chutka DS, Takahashi PY, Hoel RW. Inappropriate medications for elderly patients. Mayo Clin Proc 2004 Jan; 79(1): 122–39PubMedCrossRef Chutka DS, Takahashi PY, Hoel RW. Inappropriate medications for elderly patients. Mayo Clin Proc 2004 Jan; 79(1): 122–39PubMedCrossRef
16.
go back to reference Carnahan RM, Lund BC, Perry PJ, et al. The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice? J Am Geriatr Soc 2004 Dec; 52(12): 2082–7PubMedCrossRef Carnahan RM, Lund BC, Perry PJ, et al. The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice? J Am Geriatr Soc 2004 Dec; 52(12): 2082–7PubMedCrossRef
17.
go back to reference Roe CM, Anderson MJ, Spivack B. Use of anticholinergic medications by older adults with dementia. J Am Geriatr Soc 2002 May; 50(5): 836–42PubMedCrossRef Roe CM, Anderson MJ, Spivack B. Use of anticholinergic medications by older adults with dementia. J Am Geriatr Soc 2002 May; 50(5): 836–42PubMedCrossRef
18.
go back to reference Gill SS, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med 2005 Apr 11; 165(7): 808–13PubMedCrossRef Gill SS, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med 2005 Apr 11; 165(7): 808–13PubMedCrossRef
19.
go back to reference Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug Register: opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007 Jul; 16(7): 726–35PubMedCrossRef Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug Register: opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007 Jul; 16(7): 726–35PubMedCrossRef
21.
go back to reference Lau HS, de Boer A, Beuning KS, et al. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 1997 May; 50(5): 619–25PubMedCrossRef Lau HS, de Boer A, Beuning KS, et al. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 1997 May; 50(5): 619–25PubMedCrossRef
23.
go back to reference Johnell K, Fastbom J, Rosen M, et al. Inappropriate drug use in the elderly: a nationwide register-based study. Ann Pharmacother 2007 Jul; 41(7): 1243–8PubMedCrossRef Johnell K, Fastbom J, Rosen M, et al. Inappropriate drug use in the elderly: a nationwide register-based study. Ann Pharmacother 2007 Jul; 41(7): 1243–8PubMedCrossRef
24.
go back to reference Bergman A, Olsson J, Carlsten A, et al. Evaluation of the quality of drug therapy among elderly patients in nursing homes. Scand J Prim Health Care 2007 Mar; 25(1): 9–14PubMedCrossRef Bergman A, Olsson J, Carlsten A, et al. Evaluation of the quality of drug therapy among elderly patients in nursing homes. Scand J Prim Health Care 2007 Mar; 25(1): 9–14PubMedCrossRef
26.
go back to reference Hardell L, Carlberg M, Hansson Mild K. Use of cellular telephones and brain tumour risk in urban and rural areas. Occup Environ Med 2005 Jun; 62(6): 390–4PubMedCrossRef Hardell L, Carlberg M, Hansson Mild K. Use of cellular telephones and brain tumour risk in urban and rural areas. Occup Environ Med 2005 Jun; 62(6): 390–4PubMedCrossRef
27.
go back to reference Skelly J, Flint AJ. Urinary incontinence associated with dementia. J Am Geriatr Soc 1995 Mar; 43(3): 286–94PubMed Skelly J, Flint AJ. Urinary incontinence associated with dementia. J Am Geriatr Soc 1995 Mar; 43(3): 286–94PubMed
28.
go back to reference Lu CJ, Tune LE. Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. Am J Geriatr Psychiatry 2003 Jul–Aug; 11(4): 458–61PubMed Lu CJ, Tune LE. Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. Am J Geriatr Psychiatry 2003 Jul–Aug; 11(4): 458–61PubMed
29.
go back to reference Jewart RD, Green J, Lu CJ, et al. Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications. Am J Geriatr Psychiatry 2005 Apr; 13(4): 324–8PubMed Jewart RD, Green J, Lu CJ, et al. Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications. Am J Geriatr Psychiatry 2005 Apr; 13(4): 324–8PubMed
32.
go back to reference Schneeweiss S, Seeger JD, Maclure M, et al. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001 Nov 1; 154(9): 854–64PubMedCrossRef Schneeweiss S, Seeger JD, Maclure M, et al. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001 Nov 1; 154(9): 854–64PubMedCrossRef
Metadata
Title
Concurrent Use of Anticholinergic Drugs and Cholinesterase Inhibitors
Register-Based Study of Over 700 000 Elderly Patients
Authors
Dr Kristina Johnell
Johan Fastbom
Publication date
01-10-2008
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 10/2008
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200825100-00006

Other articles of this Issue 10/2008

Drugs & Aging 10/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.